Monitor the October 15, 2026 EGM for shareholder approval on share capital increase. Watch for SEC clearance for the Consideration Shares listing. Post-close, watch for Q4 2026 consolidated financials to confirm target EBITDA contribution and integration progress.
Price Chart
Executive Summary
Cuprina Holdings announced the acquisition of 100% of East Coast Podiatry Centre (5 clinics) and Orchard Clinic Management (2 clinics) for approximately S$4.0 million (~US$3.1 million), payable in a mix of cash (~S$3.0M) and ~301,671 Class A ordinary shares (~S$1.0M). The target group generated FY2025 unaudited revenue of ~S$9.1M and unaudited normalized EBITDA of ~S$1.2M. The deal adds an EBITDA-positive clinical platform with direct synergies to Cuprina's wound-care and collagen technologies, but the company's own financials remain loss-making and the acquisition is subject to shareholder approval and SEC clearance.
Key Facts
- Acquisition of 100% of East Coast Podiatry Centre Pte. Ltd. and Orchard Clinic Management Pte. Ltd. for ~S$4.0 million (~US$3.1 million).
- Consideration: ~S$3.0M cash (S$0.5M upon execution, S$1.35M at closing, S$1.15M deferred) and ~S$1.0M in 301,671 Class A ordinary shares (subject to lock-up).
- Target Group FY2025 unaudited revenue: ~S$9.1 million; unaudited normalized EBITDA: ~S$1.2 million.
- Consideration shares represent ~3.79% of Cuprina's enlarged issued Class A ordinary shares.
- Closing expected on or before November 1, 2026, subject to shareholder approval for share capital increase and SEC approval.
- Sellers' consideration shares subject to lock-up (2 years for Sellers II, 180 days for Seller I).
- Target Group operates 7 clinics in Singapore (5 podiatry, 2 women's health/wellness).
Financial Impact
Total deal value ~S$4.0M (~US$3.1M); target FY2025 revenue ~S$9.1M, EBITDA ~S$1.2M; Cuprina's own FY2025 net loss was $3.63M (from prior 20-F).
Risk Factors
- Closing subject to shareholder approval and SEC clearance; deal could lapse if not met by December 1, 2026.
- Target financials are unaudited management accounts; audited results may differ materially.
- Cuprina's own significant net loss of $3.63M in FY2025 and working capital outflows (per prior 20-F) raises integration and funding risk.
- Consideration shares represent ~3.79% dilution for existing shareholders.
- Sellers have outstanding sums owed to target companies (~S$1.06M total) which could create post-closing disputes.
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-045444 |
| Exhibit: ex10-1.htm | 0001493152-26-045444 |
| Exhibit: ex10-4.htm | 0001493152-26-045444 |
| Exhibit: ex10-3.htm | 0001493152-26-045444 |
| Exhibit: ex99-1.htm | 0001493152-26-045444 |
| Document: form6-k.htm | 0001493152-26-045444 |
| Document: 0001493152-26-045444-index-headers.html | 0001493152-26-045444 |
| Document: 0001493152-26-045444-index.html | 0001493152-26-045444 |
| Document: 0001493152-26-045444.txt | 0001493152-26-045444 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 6-K | $1.93 | awaiting T+5 | — | $1.85 (+4.15%) |
Oct 2, 2026 24d ago | 6-K | $2.42 $1.69 | ▼ −30.17% | ▼ −31.33% | $1.85 (−23.55%) |
Oct 2, 2026 24d ago | Press Release | $2.42 $1.69 | ▼ −30.17% | ▼ −31.33% | $1.85 (−23.55%) |
Sep 29, 2026 27d ago | 6-K | $2.28 $1.99 | ▲ +12.72% | ▲ +14.63% | $1.85 (+18.86%) |
Sep 29, 2026 27d ago | Press Release | $2.28 $1.99 | ▲ +12.72% | ▲ +14.63% | $1.85 (+18.86%) |
Sep 18, 2026 5w ago | 6-K | $1.79 $1.87 | ▼ −4.47% | ▼ −3.20% | $1.85 (−3.35%) |
Sep 17, 2026 5w ago | 6-K | $1.79 $1.87 | ▼ −4.47% | ▼ −3.20% | $1.85 (−3.35%) |
Sep 17, 2026 5w ago | Press Release | $1.79 $1.87 | ▼ −4.47% | ▼ −3.20% | $1.85 (−3.35%) |
Sep 16, 2026 5w ago | 424B4 | $1.60 $1.88 | ▼ −17.50% | ▼ −15.68% | $1.85 (−15.63%) |
Sep 16, 2026 5w ago | EFFECT | $1.60 $1.88 | ▼ −17.50% | ▼ −14.94% | $1.85 (−15.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers